The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Demina O.M.

FUV GBOU VPO RNIMU im. N.I. Pirogova Minzdrava Rossii, Moskva

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Modern etiopathogenic mechanisms of the development of rosacea and new therapies

Authors:

Demina O.M., Potekaev N.N.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2017;16(3): 13‑23

DOI: 10.17116/klinderma201716313-23

Read: 17713 times

Download PDF (RU)
Contact the author
Table of contents

MODERN ETIOPATHOGENIC MECHANISMS OF THE DEVELOPMENT OF ROSACEA AND NEW THERAPIES
MODERN ETIOPATHOGENIC MECHANISMS OF THE DEVELOPMENT OF ROSACEA AND NEW THERAPIES

To cite this article:

Demina OM, Potekaev NN. Modern etiopathogenic mechanisms of the development of rosacea and new therapies. Russian Journal of Clinical Dermatology and Venereology. 2017;16(3):13‑23. (In Russ.)
https://doi.org/10.17116/klinderma201716313-23

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Damage of human skin barrier components in expo­sure of Demo­dex specimens. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):219-226
Expe­rience of comprehensive treatment of erythematotelangiectatic rosa­cea. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):236-239
Angiopausin concentrate for skin prone to redness. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):369-374
Features of pero­xide-antioxidant imba­lance in patients with rosa­cea and approaches to comprehensive therapy. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):439-444
Hardware technologies in rosa­cea treatment. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):814-821
Abstract:

We reviewed literature on the new data about the etiology and pathogenesis of rosacea based on clinical and immunological studies, as well as modern therapeutic algorithms. It was shown that individually optimized treatment for a particular patient would result in more rapid clinical improvement followed by stable clinical remission. The use of new highly effective and safe medications ivermectin (Solantra) and brimonidine (MirvazoDerm) («Galderma, Switzerland»), provides more rapid regression of clinical symptoms and improvement of the quality of life of patients with rosacea.

Keywords:

rosacea
ivermectin
brimonidine

Authors:

Demina O.M.

FUV GBOU VPO RNIMU im. N.I. Pirogova Minzdrava Rossii, Moskva

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Close metadata

References:

  1. Adaskevich VP. Akne vul’garnye i rozovye. M: N. Novgorod: 2005. (In Russ.).
  2. Akne i rozatsea. Ed. by Potekaev NN. M. 2007. (In Russ.).
  3. Van der Linden MM, van Rappard DC, Daams JG, et al. Health-related quality of life in patients with cutaneous rosacea: a systematic review. Acta Derm Venereol 2015;95:395-400.
  4. Potekaev NN. Plazmaferez v terapii rozatsea: Diss. … kand. med. nauk. M. 1999. (In Russ.).
  5. Rusak YuE, Chernyak AYa, Solonitsa LP, Berger VV, Shepilova IV, Knyazeva GP. Helicobacter pylori u bol’nykh rozatsea. Vestnik dermatologii i venerologii. 2002;1:34-35. (In Russ.).
  6. Weston WL, Morelli JG. Steroid rosacea in prepubertal children. Arch Pediatr Adolesc Med. 2000 Jan;154(1):62-64.
  7. Diamantis S, Waldorf HA. Rosacea: clinical presentation and pathophysiology. J Drugs Dermatol. 2006 Jan;5(1):8-12.
  8. Abram K, Silm H, Maaroos HI, et al. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol. 2010;24:565-571.
  9. Kurdina MI, Potekaev NN, Potekaev SN, L’vov AN. Sovremennye predstavleniya o patogeneze rozatsea. Vestnik dermatologii i venerologii. 1998;2:16-21. (In Russ.).
  10. Chernyak AYa. Osobennosti kliniki i lecheniya rozatsea, assotsiirovannoi s khelikobakternoi infektsiei: Diss. … kand. med. nauk. Tyumen’ 2002. (In Russ.).
  11. Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015;151:1213-1219.https:/doi.org/10.1001/jamadermatol.2015.2230
  12. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, Cellular, and Molecular Aspects in the Pathophysiology of Rosacea. J Investig Dermatol Symp Proc. 2011 Dec;15(1):2-11. https:/doi.org/10.1038/jidsymp.2011.7
  13. Chang AL, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015;135:1548-1555. https:/doi.org/10.1038/jid.2015.53
  14. Butov YuS, Demina OM. K voprosu lazernoi terapii teleangiektazii. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2006;2:53-57. (In Russ.).
  15. Raznatovskii KI, Aliev FA. Dezintegratsiya tsentral’nykh predstavitel’stv vegetativnoi nervnoi sistemy u bol’nykh rozatsea. Tezisy materialov V Nauchno-prakticheskoi konferentsii «Terapiya sotsial’no-znachimykh zabolevanii v dermatovenerologii. Novye lekarstvennye preparaty i sredstva v dermatologii i kosmetologii». M. 2005;130-131. (In Russ.).
  16. Galkina OA. Primenenie shirokopolosnogo impul’snogo svetovogo izlucheniya pri lechenii patsientov s rozatsea: Diss. … kand. med. nauk. M. 2007. (In Russ.).
  17. Zandi S, Shamsadini S, Zahedi MJ, Hyatbaksh M. Helicobacter pylori and rosacea. East Mediterr Health J. 2003 Jan-Mar;9(1-2):167-171.
  18. Shugini-na EA, Potekaev NN, Ozerova RV. Vil’prafen v terapii rozatsea. Vestnik dermatologii i venerologii. 2001;2:52-53. (In Russ.).
  19. Karlova VV, Kotel’nikova IV, Chebotarev VV, Popov SP. Pilobakt v lechenii rozatsea. Voprosy dermatologii, kosmetologii, klinicheskoi mikologii i IPPP. Sbornik trudov yubileinoi konferentsii. Ed. by Butov YuS. M. 2005;89-91. (In Russ.).
  20. Molochkov AV, Sin’kevich ER, Tsodikov GV, Matevosov DYu. Rol’ Helicobacter pylori v etiopatogeneze rozatsea. Tezisy materialov V Nauchno-prakticheskoi konferentsii «Terapiya sotsial’no-znachimykh zabolevanii v dermatovenerologii. Novye lekarstvennye preparaty i sredstva v dermatologii i kosmetologii». M. 2005;94-95. (In Russ.).
  21. Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol. 2015;73:604-608. https:/doi.org/10.1016/j.jaad.2015.07.009
  22. Hua TC, Chung PI, Chen YJ, et al. Cardiovascular comorbidities in patients with rosacea: a nationwide case-control study from Taiwan. J Am Acad Dermatol. 2015;73:249-254. https:/doi.org/10.1016/j.jaad.2015.04.028
  23. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Clustering of autoimmune diseases in patients with rosacea. J Am Acad Dermatol. 2016;74:667-672.https:/doi.org/10.1016/j.jaad.2015.11.004
  24. Haenen CC, Kouwenhoven ST, van Doorn R. Rosacea fulminans in pregnancy. Ned Tijdschr Geneeskd. 2015;159(0):A8334.
  25. Flint ID, Wilkin JK. Acquired persistent erythematous patch on the neck. Acquired nevus flammeus. Arch Dermatol. 1994;130:509, 512.
  26. Huggenberger R, Detmar M. The cutaneous vascular system in chronic skin inflammation. J Investig Dermatol Symp Proc. 2011;15:24-32.
  27. McAleer MA, Fitzpatrick P, Powell FC. Papulopustular rosacea: prevalence and relationship to photodamage. J Am Acad Dermatol. 2010;63:33-39.
  28. Wilkin JK. Oral thermal-induced flushing in erythematotelangiectatic rosacea. J Invest Dermatol. 1981;76:15-18.
  29. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341.
  30. Dahl MV, Rosas AJ, Schlievert PM. Temperature regulates bacterial protein production: possible role in rosacea. J Am Acad Dermatol. 2004;50:266-272.
  31. Roosterman D, Goerge T, Schneider SW, et al. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86:1309-1379.
  32. Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc. 2011;15:33-39.
  33. Craige H, Cohen JB. Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol. J Am Acad Dermatol. 2005;53:881-884.
  34. Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143:1369-1371.
  35. Gallo R, Drago F, Paolino S, et al. Rosacea treatments: what’s new and what’s on the horizon? Am J Clin Dermatol. 2010;11:299-303.
  36. Powell FC. Clinical practice. Rosacea. N Engl J Med. 2005;352:793-803; Lazaridou E, Giannopoulou C, Fotiadou C, et al. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges. 2011;9:21-25.
  37. Mc Aleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144:663-671.
  38. Gallo R, Drago F, Paolino S, et al. Rosacea treatments: what’s new and what’s on the horizon? Am J Clin Dermatol. 2010;11:299-303.
  39. Tuzun Y, Keskin S, Kote E. The role of Helicobacter pylori infection in skin diseases: facts and controversies. Clin Dermatol. 2010;28:478-482.
  40. Lazaridou E, Giannopoulou C, Fotiadou C, et al. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges. 2011;9:21-25.
  41. Lazaridou E, Apalla Z, Sotiraki S, et al. Clinical and laboratory study of rosacea in northern Greece. J Eur Acad Dermatol Venereol. 2010;24:410-414.
  42. Lacey N, Delaney S, Kavanagh K, et al. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007;157:474-481.
  43. McAleer MA, Fitzpatrick P, Powell FC. Papulopustular rosacea: prevalence and relationship to photodamage. J Am Acad Dermatol. 2010;63:33-39.
  44. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13:975-980.
  45. Morizane S, Yamasaki K, Kabigting FD, et al. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J Invest Dermatol. 2010;130:1297-1306.
  46. Rufli T, Buchner SA. T-cell subsets in acne rosacea lesions and the possible role of Demodex folliculorum. Dermatologica. 1984;169:1-5.
  47. Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch Dermatol. 1969;100:683-691.
  48. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206.
  49. Aroni K, Tsagroni E, Kavantzas N, et al. A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res. 2008;300:125-131.
  50. Ramelet AA, Perroulaz G. Rosacea: histopathologic study of 75 cases. Ann Dermatol Venereol. 1988;115:801-806.
  51. Akamatsu H, Oguchi M, Nishijima S, et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res. 1990;282:449-454.
  52. Millikan L. The proposed inflammatory pathophysiology of rosacea: implications for treatment. Skinmed. 2003;2:43-47.
  53. Aloi F, Tomasini C, Soro E, et al. The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol. 2000;42:468-472.
  54. Steinhoff M, Sulk M, Schwab V, et al. Molecular and morphometric characterization of neuroinflammatory and neurovascular changes in the development of rosacea. J Invest Dermatol. 2010;130(Suppl 11):15;abstract 088.
  55. Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53-62.
  56. Gerber PA, Buhren BA, Steinhoff M, et al. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15:40-47.
  57. Gomaa AH, Yaar M, Eyada MM, et al. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol. 2007;34:748-753.
  58. Smith JR, Lanier VB, Braziel RM, et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol. 2007;91:226-229.
  59. Aroni K, Tsagroni E, Kavantzas N, et al. A study of the pathogenesis of rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res. 2008;300:125-131.
  60. Bender A, Zapolanski T, Watkins S, et al. Tetracycline suppresses ATP gamma S-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells. Exp Dermatol. 2008;17:752-760.
  61. Nakamura K, Rockson SG. Molecular targets for therapeutic lymphangiogenesis in lymphatic dysfunction and disease. Lymphat Res Biol. 2008;6:181-189.
  62. Ogunbiyi S, Chinien G, Field D, et al. Molecular characterization of dermal lymphatic endothelial cells from primary lymphedema skin. Lymphat Res Biol. 2011;9:19-30.
  63. Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53-62.
  64. Roosterman D, Goerge T, Schneider SW, et al. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86:1309-1379.
  65. Graepel R, Fernandes ES, Aubdool AA, et al. 4-Oxo-2-nonenal (4-ONE): evidence of transient receptor potential ankyrin 1-dependent and -independent nociceptive and vasoactive responses in vivo. J Pharmacol Exp Ther. 2011;337:117-124.
  66. Hua S, Cabot PJ. Mechanisms of peripheral immune-cell-mediated analgesia in inflammation: clinical and therapeutic implications. Trends Pharmacol Sci. 2010;31:427-433.
  67. Muller WA. Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol. 2011;6:323-344.
  68. Gerber PA, Buhren BA, Steinhoff M, et al. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15:40-47.
  69. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15:12-15.
  70. Meyer-Hoffert U, Schröder J-M. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc. 2011;15:16-23.
  71. Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc. 2011;15:33-39.
  72. Meyer-Hoffert U, Schröder J-M. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc. 2011;15:16-23.
  73. Schechter BA, Katz RS, Friedman LS. Efficacy of topical cyclosporine for the treatment of ocular rosacea. Adv Ther. 2009;26:651-659. https:/doi.org/10.1007/s12325-009-0037-2
  74. Fowler J, et al. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012 Mar;166(3):633-641. https:/doi.org/10.1111/j.1365-2133.2011.10716.x
  75. Fowler J, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013 Jun 1;12(6):650-656.
  76. Moore A, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014 Jan;13(1):56-61.
  77. Del Rosso J, et al.Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92:234-240.
  78. Tanghetti E, et al.Optimizing the use of topical brimonidine in rosacea management: panel recommendations. J Drugs Dermatol. 2014;14(1):33-40.
  79. Say EM, Okan G, Gökdemir G. Treatment outcomes of long-pulsed Nd: YAG laser for two different subtypes of rosacea. J Clin Aesthet Dermatol. 2015;8:16-20.
  80. Butterwick KL, Butterwick LS, Han A. Laser and light therapies for acne rosacea. J Drugs Dermatol. 2006 Jan;5(1):35-39.
  81. Butov YuS, Demina OM. K voprosu lazernoi terapii teleangiektazii. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2006;2:53-57. (In Russ.).
  82. Svyatenko T, Starostina O. New opportunities of IPL-therapy in complex treatment of the rosacea vascular forms. Georgian Med News. 2015;243: 62-66.
  83. Liu J, Liu J, Ren Y, Li B, Lu S. Comparative efficacy of intense pulsed light for different erythema associated with rosacea. J Cosmet Laser Ther. 2014;16:324-327.
  84. Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology. 2015;230:299-301.
  85. van Zuuren EJ, Kramer SF, Carter BR, Graber MA, Fedorowicz Z. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol. 2011;165:760-781.
  86. Stein Gold L, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014 Mar;13(3):316-323.
  87. Taieb A. Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015 Apr;172(4):1103-1110. https:/doi.org/10.1111/bjd.13408. Epub 2015 Feb11
  88. Altinyazar H.C., Koca R., Tekin N.S., Esturk E. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol. 2005 Mar;44(3):252-255.
  89. Elewski BE. Rosacea trial comparing twice-daily azelaic acid gel 15% with once-daily metronidazole gel 1%. Cutis 2007;79:57-58.
  90. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55:77-81.
  91. Arman A, Demirseren DD, Takmaz T.Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int J Ophthalmol. 2015 Jun 18;8(3):544-549. https:/doi.org/10.3980/j.issn.2222-3959.2015.03.19. eCollection2015
  92. Akhtyamov SN, Butov YuS. Prakticheskaya dermatokosmetologiya: Uchebnoe posobie. M.: Meditsina. 2003;270-277. (In Russ.).
  93. Butov YuS, Akilov OE. Klinicheskie osobennosti i voprosy klassifikatsii demodikoza kozhi. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei. 2003;2:53-58. (In Russ.).
  94. Sergeev YuV, Cherkasova MV. Klinicheskii opyt i otdalennye rezul’taty lecheniya bol’nykh rozatsea ornidazolom (tiberal). Tezisy materialov V Nauchno-prakticheskoi konferentsii «Terapiya sotsial’no-znachimykh zabolevanii v dermatovenerologii. Novye lekarstvennye preparaty i sredstva v dermatologii i kosmetologii». M. 2004;167-168. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.